A microRNA that regulates inflammation shows promise as a treatment for inflammatory diseases such as asthma and cancer, according to research published in Cell Reports.
The microRNA, known as miR-223, is highly expressed in blood cells that cause inflammation (neutrophils). When they’re working correctly, those blood cells help protect the human body against infections, but sometimes they damage host tissue instead of microbes, causing chronic inflammation and disease.
To uncover the link between miR-223 and inflammation, a Purdue University research team created a zebrafish totally deficient of miR-223. Then they cut off a small chunk of its fin.
“The inflammation was really robust,” said Qing Deng, a professor of biological sciences at Purdue and corresponding author of the paper. “Neutrophils accumulated at the wound and they just kept coming. This is consistent with the literature, but we wanted to understand why.”
Extensive gene expression analysis led them to pathway NF-kB, a protein complex found in nearly all animal cell types that regulates inflammation and cell proliferation. Heightened activation of this pathway is the cause of increased inflammation, although it’s limited to the deeper, or basal, layer of the epithelium. This means any therapeutics would need to reach the basal layer to work.
The same pathway plays an important role in human bronchial epithelial cells, which are critical in the development of asthma, according to the study. MiR-223 suppresses the pathway, which means supplementing it to epithelial cells could help control inflammatory disease.
“We don’t have human trials yet, but we think it’s promising,” Deng said. “Instead of using steroids to drive away the immune cells, maybe this microRNA could be given.”
Learn more: MicroRNA could help treat cancer and asthma
The Latest on: MicroRNA
[google_news title=”” keyword=”MicroRNA” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: MicroRNA
- How mRNA Is Rewriting the Rules of Cancer Treatmenton April 24, 2024 at 2:24 pm
MIT spinout Strand Therapeutics has developed a new class of mRNA molecules that can sense where they are in the body, for more targeted and powerful treatments. What if training your immune system to ...
- Stem Cell Magic: Scientists Unveil New Superhero for Healing Diabetes Woundson April 23, 2024 at 10:13 am
Researchers unveiled a novel therapy for diabetic wound healing. The new research highlights the use of exosomal miR-4645-5p from hypoxic bone marrow mesenchymal stem cells (BMSCs) to significantly ...
- Duke mechanical engineers develop more efficient diagnostic platform for cancer, other diseaseson April 22, 2024 at 4:48 pm
A team of mechanical engineers has created a new diagnostic platform that can be used to detect various cancers and other serious medical conditions with greater efficiency.
- German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipelineon April 18, 2024 at 10:55 am
Novo Nordisk's acquisition of Cardior Pharmaceuticals clears regulatory hurdles, advancing cardiovascular treatment development with CDR132L. Learn about the promising phase 2 trials and strategic ...
- Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Studyon April 18, 2024 at 4:36 am
BB-301 facilitated improvements across multiple measures of swallowing function in the first Phase 1b/2a clinical study subject as compared to pretreatment assessments conducted during the ...
- La Jolla News Nuggets: Free-speech pads, Scientist of the Year, Tour d’Elegance parade, Pirch layoffs, moreon April 16, 2024 at 5:01 pm
The three-day La Jolla Concours d’Elegance festivities kick off Friday, April 19, with a VIP party and also will include “Porsches on Prospect” on Saturday and the traditional car show in Scripps Park ...
- Arkansas Children’s, UAMS awarded $3.2 million NIH granton April 16, 2024 at 3:01 pm
The National Institute of Health awarded $3.2 million to Arkansas Children’s and the University of Arkansas for Medical Sciences to innovate new treatment options for children with rare vascular ...
- UAMS, Arkansas Children’s awarded $3.2 million to develop next-generation treatments for rare children’s anomalyon April 16, 2024 at 12:27 pm
“The development of transdermal microRNA therapeutics that silence the genes responsible for lymphatic malformation growth could significantly improve the quality of life of these children.” Officials ...
- Breast Milk Contains All the Nutrients a Baby Needs?on April 13, 2024 at 4:00 pm
Breastmilk provides all the energy and nutrients that the infant needs for the first months of life, and it continues to provide up to half or more of a child's nutritional needs during the second ...
- This outdated diabetes drug still has something to offeron April 11, 2024 at 4:08 pm
Researchers have discovered the biochemical workings of an old-fashioned diabetes drug, and it's helping them develop new, safer alternatives.
via Bing News
